Stock Events

Stock Events

OmniAb 

$4.75
23
-$0.29-5.75% Thursday 20:00
+$0.03+0.63%Thursday 23:44After hours

Statistics

Day High
4.75
Day Low
4.73
52W High
5.43
52W Low
1.3
Volume
44,459
Avg. Volume
-
Mkt Cap
690.6M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.17
-0.13
-0.09
-0.05
Expected EPS
-0.127143
Actual EPS
N/A

Financials

-347.04%Profit Margin
Unprofitable
2021
2022
2023
2024
2025
18.67MRevenue
-64.78MNet Income

Analyst Ratings

11.00Average Price Target
The highest estimate is 11.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OABI. It's not an investment recommendation.
Ares Capital
6
ARCC
Microsoft
5
MSFT
NVIDIA
5
NVDA
Mastercard Incorporated
5
MA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is a leading biotech company that competes with OmniAb in the development of monoclonal antibodies for various therapeutic areas.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biopharmaceutical company that competes in the discovery, development, and manufacturing of human therapeutics, including monoclonal antibodies, similar to OmniAb's focus.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company is a competitor due to its strong focus on antibody therapies, including its efforts in immunology and oncology, areas that overlap with OmniAb's interests.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences competes with OmniAb in the biopharmaceutical field, particularly in the development of treatments that involve monoclonal antibodies for infectious diseases, among others.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb is involved in the discovery and development of innovative medicines, including monoclonal antibodies for cancer and other diseases, making it a competitor to OmniAb.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. competes with OmniAb through its extensive research and development in biopharmaceuticals, including therapies based on monoclonal antibodies for various diseases.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical company that competes with OmniAb in the development and commercialization of biopharmaceuticals, including monoclonal antibodies for a wide range of conditions.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is a competitor because of its focus on the development of biopharmaceuticals, including monoclonal antibodies for the treatment of diseases in areas like oncology, which overlaps with OmniAb's focus.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG competes with OmniAb through its subsidiary Genentech in the research and development of monoclonal antibody therapies, particularly in oncology and immunology.
Sanofi
SNY
Mkt Cap107.39B
Sanofi competes with OmniAb in the global healthcare market, particularly in the development of monoclonal antibodies for immunological diseases, an area of focus for OmniAb.

About

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
Show more...
CEO
Matthew W. Foehr
Employees
89
Country
United States
ISIN
US68218J1034

Listings

XNAS
US
OABI
XNAS
US
OABIW
BOATS
BOATS
OABI.BOATS

0 Comments

Share your thoughts

FAQ

What is OmniAb stock price today?▼
The current price of OABI is $4.75 USD — it has decreased by -5.75% in the past 24 hours. Watch OmniAb stock price performance more closely on the chart.
What is OmniAb stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange OmniAb stocks are traded under the ticker OABI.
Is OmniAb stock price growing?▼
OABI stock has risen by +6.26% compared to the previous week, the month change is a +137.5% rise, over the last year OmniAb has showed a +196.87% increase.
What is OmniAb market cap?▼
Today OmniAb has the market capitalization of 690.6M
When is the next OmniAb earnings date?▼
OmniAb is going to release the next earnings report on November 17, 2026.
What were OmniAb earnings last quarter?▼
OABI earnings for the last quarter are -0.05 USD per share, whereas the estimation was -0.12 USD resulting in a +58.33% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is OmniAb revenue for the last year?▼
OmniAb revenue for the last year amounts to 18.67M USD.
What is OmniAb net income for the last year?▼
OABI net income for the last year is -64.78M USD.
How many employees does OmniAb have?▼
As of September 04, 2026, the company has 89 employees.
In which sector is OmniAb located?▼
OmniAb operates in the Health & Wellness sector.
When did OmniAb complete a stock split?▼
OmniAb has not had any recent stock splits.
Where is OmniAb headquartered?▼
OmniAb is headquartered in EMERYVILLE, United States.